U.S. markets closed

CRISPR Therapeutics AG (CRSP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
52.33+1.31 (+2.57%)
At close: 04:00PM EST
52.23 -0.10 (-0.19%)
After hours: 05:39PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close51.02
Bid52.00 x 2200
Ask52.35 x 2200
Day's Range50.36 - 53.04
52 Week Range38.94 - 86.95
Avg. Volume1,079,293
Market Cap4.097B
Beta (5Y Monthly)1.60
PE Ratio (TTM)13.92
EPS (TTM)3.76
Earnings DateNov 01, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est95.30
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Near Fair Value
-7% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for CRSP

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CRISPR Therapeutics AG
    Analyst Report: CRISPR Therapeutics AGCRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
    Fair Value
    Economic Moat
    3 months agoMorningstar
View more
  • Motley Fool

    3 Things About CRISPR Therapeutics That Smart Investors Know

    It's easy to see why investors might assume that early-stage gene-editing companies like CRISPR Therapeutics (NASDAQ: CRSP) are too inscrutable to approach. In fact, smart investors know (at least) three key things about this business, and you should too -- especially if you're considering purchasing shares sometime soon. CRISPR has a few partners, but its most important one by far is Vertex Pharmaceuticals (NASDAQ: VRTX).

  • Zacks

    CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

    CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $50.47, moving -0.55% from the previous trading session.

  • InvestorPlace

    3 Gene Editing Stocks With the Best Long-Term Potential

    Gene editing stocks present themselves as one of the more lucrative investments in the healthcare sector. Gene editing, a revolutionary take on the science of genetic engineering, has the potential to countless lives around the globe. By introducing genetic material into cells, scientists can correct genetic abnormalities in a way never seen before. With the potential for vast improvements, gene therapy and gene editing are promising modern biotechnology forms.InvestorPlace - Stock Market News,